New drug can ease the side effects of medication against severe depression
A new substance named Lu AF60097 may help reduce side effects from tricyclic antidepressants in those with severe depression.... Read More...
MDD
The largest genetic map of psychiatric disorders so far
The largest genetic map of mental health disorders to date reveals there are three groups of highly genetically related disorders among eight psychiatric disorders. A gene related to nervous system development is a risk factor for all eight disorders studied. The RBFOX1 gene is implicated in seven of the eight disorders. ADHD and depression share 44% of genetic risk factors common in the general population. 109 pleiotropic loci affect more than one disorder. These pleiotropic loci are within genes that show heightened expression in the brain through the lifespan, beginning during the second trimester of pregnancy.... Read More...
Decision time predicts the risk of depression relapse
Findings reveal it is possible to predict the risk of a person with MDD lapsing back into depression after stopping antidepressants. Those who relapse take longer to decide how much effort to invest for a reward.... Read More...
New biochemical ‘warning sign’ of early-stage depression identified
High levels of anthranilic acid in the blood may be a new biomarker for assessing the risk of developing major depressive disorder.... Read More...
Early-life exposure to dogs may lessen risk of developing schizophrenia
Exposure to household pet dogs in the early years of life was associated with a significantly decreased risk of being diagnosed with schizophrenia later in life.... Read More...
Want to avoid the holiday blues? Skip the sweet treats
If you are prone to depression, a new study suggests you should avoid indulging on dietary sugars. Added sugars have a pro-inflammatory effect on depressive disorders.... Read More...
Imaging reveals pathways behind depression
Two new neuroimaging studies shed light on structural and functional abnormalities in the brains of those with major depressive disorder.... Read More...
Side effects mild and brief with single antidepressant dose of intravenous ketamine
The side effects of administering ketamine to treat major depressive disorder are mild and persist for no longer than four hours, researchers report. Most of the side effects peaked within an hour of treatment, and many patients reported the effects as being significantly reduced two hours post ketamine administration.... Read More...
Who will get depressed under major stress? Study shows promise of genetic risk prediction
A polygenetic risk score for major depressive disorder may reveal those most at risk of developing depression during times of extreme stress.... Read More...
Neurofeedback increases self-esteem by re-balancing brain circuits in depression
Neurofeedback training can alter guilt-related networks and improve self-esteem in those with major depressive disorder.... Read More...
Long-term study data shows DBS is effective treatment for most severe form of depression
Long term outcome data of patients with treatment-resistant depression found subcallosal cingulate deep brain stimulation (SCC DBS) was both effective at relieving symptoms and safe.... Read More...
People with anxiety may strategically choose worrying over relaxing
Those with anxiety and depressive disorders may actively resist relaxation, especially if they are more sensitive to shifts in negative emotions. ... Read More...